PHARMA SIGNALOPEN RESEARCH PLATFORM →
CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity

NCT07469800 · Phase 3 · Recruiting

PHASEPhase 3
STATUSRecruiting
ENROLLMENT336
EST. COMPLETION2026-08-01

Conditions

OverweightObesityHypertensive

Interventions

IBI362Placebo

Study details

SPONSORInnovent Biologics (Suzhou) Co. Ltd.
START DATE2026-04-23

Related company profiles

Innovent Biologics

1801.HK

Primary source

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier
NCT07469800
Event / action date
Not separately retained
Source update date
Not separately retained
Platform retrieval / processing date
Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record